IT1045912B - Proteina supportata e procedimento per la sua preparazione - Google Patents

Proteina supportata e procedimento per la sua preparazione

Info

Publication number
IT1045912B
IT1045912B IT30523/73A IT3052373A IT1045912B IT 1045912 B IT1045912 B IT 1045912B IT 30523/73 A IT30523/73 A IT 30523/73A IT 3052373 A IT3052373 A IT 3052373A IT 1045912 B IT1045912 B IT 1045912B
Authority
IT
Italy
Prior art keywords
procedure
preparation
supported protein
protein
supported
Prior art date
Application number
IT30523/73A
Other languages
English (en)
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2260185A external-priority patent/DE2260185C3/de
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Application granted granted Critical
Publication of IT1045912B publication Critical patent/IT1045912B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/18—Multi-enzyme systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F289/00—Macromolecular compounds obtained by polymerising monomers on to macromolecular compounds not provided for in groups C08F251/00 - C08F287/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C12N11/087—Acrylic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IT30523/73A 1972-12-08 1973-10-24 Proteina supportata e procedimento per la sua preparazione IT1045912B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2260185A DE2260185C3 (de) 1971-06-09 1972-12-08 Trägergebundenes Protein und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
IT1045912B true IT1045912B (it) 1980-06-10

Family

ID=5863935

Family Applications (1)

Application Number Title Priority Date Filing Date
IT30523/73A IT1045912B (it) 1972-12-08 1973-10-24 Proteina supportata e procedimento per la sua preparazione

Country Status (12)

Country Link
US (1) US3969287A (it)
JP (1) JPS5749197B2 (it)
BE (1) BE808354A (it)
CA (1) CA1023287A (it)
CH (1) CH619003A5 (it)
DK (1) DK141555C (it)
HU (1) HU169972B (it)
IL (1) IL43476A (it)
IT (1) IT1045912B (it)
SE (1) SE420498B (it)
SU (1) SU524521A3 (it)
ZA (1) ZA739318B (it)

Families Citing this family (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593992A5 (it) * 1972-12-23 1977-12-30 Roehm Gmbh
GB1550819A (en) * 1975-06-04 1979-08-22 Nat Res Dev Polymeric support for biogically active materials
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
US4108804A (en) * 1975-12-23 1978-08-22 Toru Seita Process for preparation of chromatography solid supports comprising a nucleic acid base-epoxy group containing porous gel
US4046723A (en) * 1976-04-22 1977-09-06 The Dow Chemical Company Azide bonding of a protein to a latex
US4206261A (en) * 1976-06-09 1980-06-03 Schenectady Chemicals, Inc. Water-soluble polyester imide resin wire coating process
US4179423A (en) * 1976-06-09 1979-12-18 Schenectady Chemicals, Inc. Water-soluble polyester imide resins
US4045384A (en) * 1976-07-23 1977-08-30 The Dow Chemical Company Method for forming an amide bond between a latex and protein
DE2708018A1 (de) * 1977-02-24 1978-09-07 Boehringer Mannheim Gmbh An polyamid fixiertes biologisch aktives protein und verfahren zu seiner herstellung
DE2862449D1 (en) * 1977-08-22 1984-11-22 Nat Res Dev Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
US4206286A (en) * 1977-11-14 1980-06-03 Technicon Instruments Corporation Immobilization of proteins on inorganic supports
US4338398A (en) * 1979-03-20 1982-07-06 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Immobilization of starch degrading enzymes
US4415665A (en) * 1980-12-12 1983-11-15 Pharmacia Fine Chemicals Ab Method of covalently binding biologically active organic substances to polymeric substances
DE3126551C2 (de) * 1981-07-04 1983-12-15 Rolf Dr. 8700 Würzburg Siegel Herstellungsverfahren für Materialien zur Immobilisierung von Proteinen und Kohlenhydratgruppen
US4506019A (en) * 1982-09-24 1985-03-19 Leeco Diagnostics, Inc. Activated polymer container means and assay method employing the same
US4596777A (en) * 1983-08-10 1986-06-24 E. R. Squibb & Sons, Inc. Process for preparing (3S)-3-[[[2-(protected or unprotected amino)-4-thiazolyl]acetyl]amino]-2-oxo-1-azetidinesulfonic acid and 4-substituted derivatives thereof
US4843010A (en) * 1983-11-10 1989-06-27 Genetic Systems Corporation Polymerization-induced separation immunoassays
US4609707A (en) * 1983-11-10 1986-09-02 Genetic Systems Corporation Synthesis of polymers containing integral antibodies
EP0142810B1 (en) * 1983-11-10 1994-02-16 Genetic Systems Corporation Polymerizable compounds integrally containing antibodies and their uses in polymerization induced separation immunoassays
US4752638A (en) * 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
US4511478A (en) * 1983-11-10 1985-04-16 Genetic Systems Corporation Polymerizable compounds and methods for preparing synthetic polymers that integrally contain polypeptides
US4711840A (en) * 1984-01-27 1987-12-08 Genetic Systems Corporation Polymerization-induced separation immunoassays
JPH0820447B2 (ja) * 1984-01-27 1996-03-04 ジェネティック システムズ コーポレーション 液体混合物から物質を分離する方法及び免疫評価法
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4749647A (en) * 1984-06-22 1988-06-07 Genetic Systems Corporation Polymerization-induced separation assay using recognition pairs
DE3784592T2 (de) * 1986-08-07 1993-09-23 Minnesota Mining & Mfg Stabile, biologisch-aktive, fluorchemische emulsionen.
US4808530A (en) * 1986-09-05 1989-02-28 The Ohio State University Protein immobilization by adsorption of a hydrophobic amidine protein derivative to a hydrophobic surface
US4885250A (en) * 1987-03-02 1989-12-05 E. I. Du Pont De Nemours And Company Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports
US5063109A (en) * 1988-10-11 1991-11-05 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0473961B1 (en) * 1990-08-15 1996-01-03 Abbott Laboratories Immunoassay reagents and method for determining cyclosporine
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5482996A (en) * 1993-12-08 1996-01-09 University Of Pittsburgh Protein-containing polymers and a method of synthesis of protein-containing polymers in organic solvents
JP3805785B2 (ja) 1994-01-11 2006-08-09 ダイアックス コープ． カリクレイン阻害クニッツドメイン蛋白質およびその相同体
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6045797A (en) * 1994-03-14 2000-04-04 New York University Medical Center Treatment or diagnosis of diseases or conditions associated with a BLM domain
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5736624A (en) * 1994-12-02 1998-04-07 Abbott Laboratories Phosphatase activated crosslinking, conjugating and reducing agents; methods of using such agents; and reagents comprising phosphatase activated crosslinking and conjugating agents
US5837524A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polynucleotide products
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5807989A (en) * 1994-12-23 1998-09-15 New York University Methods for treatment or diagnosis of diseases or disorders associated with an APB domain
US6300482B1 (en) * 1995-01-03 2001-10-09 Max-Flanck-Gesellschaft Zuer For{Overscore (D)}Erung Der MDKI, a novel receptor tyrosine kinase
US6565842B1 (en) * 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
CA2231850A1 (en) 1995-09-15 1997-03-20 Sergio Onate Steroid receptor coactivator compositions and methods of use
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
AU735200B2 (en) * 1996-04-01 2001-07-05 Genentech Inc. APO-2LI and APO-3 apoptosis polypeptides
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) * 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
DE69737457T2 (de) 1997-01-31 2007-11-29 Genentech, Inc., South San Francisco O-fukosyltransferase
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
JP2001511653A (ja) * 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Ａｐｏ−２レセプター
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
CA2293724C (en) 1997-06-05 2010-02-02 Xiaodong Wang Apaf-1, the ced-4 human homolog, an activator of caspase-3
JP2002508663A (ja) * 1997-06-18 2002-03-19 ジェネンテク，インコーポレイテッド Ａｐｏ−２ＤｃＲ
AU8569698A (en) 1997-07-11 1999-02-08 Brandeis University Method of inducing apoptosis by reducing the level of thiamin
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
IL134577A0 (en) * 1997-08-26 2001-04-30 Genentech Inc Rtd receptor
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
EP1045906B1 (en) 1998-01-15 2008-10-15 Genentech, Inc. Apo-2 ligand
ES2331901T3 (es) * 1998-06-12 2010-01-19 Genentech, Inc. Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la produccion de los mismos.
US6984719B1 (en) 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US6368793B1 (en) * 1998-10-14 2002-04-09 Microgenomics, Inc. Metabolic selection methods
AU773891C (en) * 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6982153B1 (en) 1998-12-03 2006-01-03 Targanta Therapeutics, Inc. DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides
US6861442B1 (en) 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
AU779689B2 (en) * 1999-06-16 2005-02-03 Icos Corporation Human poly(ADP-ribose) polymerase 2 materials and methods
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
US20030138771A1 (en) * 1999-09-30 2003-07-24 Jerry Pelletier DNA sequences from S. pneumoniae bacteriophage DP1 that encode anti-microbal polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
ES2256066T3 (es) * 1999-11-16 2006-07-16 Genentech, Inc. Elisa para vegf.
CA2407083A1 (en) 2000-04-21 2001-11-01 Amgen Inc. Apo-ai/aii peptide derivatives
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
WO2002013861A2 (en) * 2000-08-11 2002-02-21 Favrille, Inc. Method and composition for altering a t cell mediated pathology
MXPA03010210A (es) 2001-05-11 2004-03-10 Amgen Inc Peptidos y moleculas relacionadas que se enlazan a tall-1.
CN105131104B (zh) 2001-10-10 2018-11-16 诺和诺德公司 肽的重构和糖缀合
DK1578771T3 (da) 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20040054082A1 (en) * 2001-12-03 2004-03-18 Bank David H Toughened polymer blends with improved surface properties
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
US7521530B2 (en) * 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
ES2709103T3 (es) * 2002-08-28 2019-04-15 Dyax Corp Métodos para conservar órganos y tejidos
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
WO2005079779A1 (en) * 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
BRPI0509419A (pt) * 2004-04-16 2007-09-04 Genentech Inc método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio
ES2605792T3 (es) * 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
WO2005114218A2 (en) * 2004-05-15 2005-12-01 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
EP1755609A1 (en) * 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
EP1773400A2 (en) * 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
CA2580796C (en) * 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006069403A2 (en) 2004-12-22 2006-06-29 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
AU2006214190A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007056411A2 (en) * 2005-11-08 2007-05-18 Genentech, Inc. Method of producing pan-specific antibodies
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
WO2007106746A2 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
EP2037928B1 (en) 2006-06-26 2012-01-11 Amgen Inc. Methods for treating atherosclerosis
US7884180B2 (en) 2006-09-18 2011-02-08 Compugen Ltd Peptides which bind to G protein-coupled receptors
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
DK2069798T3 (da) 2006-10-04 2014-06-16 Genentech Inc Elisa til vegf
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
US7825093B2 (en) 2006-10-25 2010-11-02 Amgen Inc. Methods of using OSK1 peptide analogs
WO2008079322A1 (en) * 2006-12-22 2008-07-03 Beckman Coulter, Inc. Methods, kits and materials for diagnosing disease states by measuring isoforms or proforms of myeloperoxidase
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP2167534B1 (en) 2007-07-12 2012-07-04 Compugen Ltd. Bioactive peptides and method of using same
DK2181190T3 (da) 2007-07-26 2014-03-31 Amgen Inc Modificerede lecithin-kolesterol-acyltransferase-enzymer
US8715684B2 (en) 2007-08-28 2014-05-06 Ramot At Tel Aviv University Ltd. Peptides inducing a CD4i conformation in HIV gp120 while retaining vacant CD4 binding site
EP3575317A1 (en) 2007-12-26 2019-12-04 Xencor, Inc. Fc variants with altered binding to fcrn
WO2010027802A2 (en) 2008-08-25 2010-03-11 New York University Methods for treating diabetic wounds
CN104042618B (zh) 2008-11-13 2018-02-16 吉利德卡利斯托加公司 恶性血液病的治疗
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EA201101507A1 (ru) * 2009-04-20 2012-05-30 Гилеад Калистога Ллс. Способы лечения солидных опухолей
EP2456443A1 (en) 2009-07-21 2012-05-30 Gilead Calistoga LLC Treatment of liver disorders with pi3k inhibitors
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
NZ599600A (en) * 2009-10-26 2015-04-24 Genentech Inc Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
AP2012006294A0 (en) 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
CN103068824B (zh) 2010-05-17 2017-09-08 印蔻真治疗公司 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]***并[4,5‑b]吡啶化合物
US9254310B2 (en) 2010-06-17 2016-02-09 New York University Therapeutic and cosmetic uses and applications of calreticulin
WO2012030738A2 (en) 2010-08-30 2012-03-08 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
KR20140145947A (ko) 2011-03-16 2014-12-24 암젠 인크 Nav1.3과 nav1.7의 유효한 선별적 저해제
MX2013012284A (es) 2011-04-29 2013-11-21 Bristol Myers Squibb Co Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
WO2012151525A1 (en) 2011-05-04 2012-11-08 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP2758437B1 (en) 2011-09-22 2020-06-03 Amgen Inc. Cd27l antigen binding proteins
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EA201691327A1 (ru) 2012-03-05 2017-03-31 Джилид Калистога Ллс Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
WO2013142796A2 (en) 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
BR112014024023A2 (pt) 2012-03-28 2017-07-18 Genentech Inc anticorpos idiotípicos anti-hcmv e usos dos mesmos
BR112014024251A8 (pt) 2012-03-30 2018-01-23 Rhizen Pharmaceuticals S A novos compostos piridina 3,5-dissubstituída-3h-imidazo [4,5-b] e piridina 3,5-dissubstituída -3h-[1,2,3]triazolo[4,5-b] como moduladores de quinases de proteína c-met
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
ES2875957T3 (es) 2012-12-20 2021-11-11 Amgen Inc Agonistas del receptor APJ y usos de los mismos
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
EP2954332A1 (en) 2013-02-06 2015-12-16 Pieris AG Novel lipocalin-mutein assays for measuring hepcidin concentration
WO2014124487A1 (en) 2013-02-18 2014-08-21 Vegenics Pty Limited Ligand binding molecules and uses thereof
EP2970408B1 (en) 2013-03-12 2018-01-10 Amgen Inc. Potent and selective inhibitors of nav1.7
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
PL3587448T3 (pl) 2013-03-15 2021-11-29 Xencor, Inc. Białka heterodimeryczne
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
ES2753950T3 (es) 2013-03-15 2020-04-15 Amgen Res Munich Gmbh Moléculas de unión monocatenarias que comprenden ABP del extremo N
JP6603207B2 (ja) 2013-03-15 2019-11-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ヌトリン３ａおよびペプチドを用いた肺線維症の阻害
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
EA201592285A1 (ru) 2013-05-30 2016-05-31 Байоджен Ма Инк. Антигенсвязывающие белки к рецептору онкостатина м
EP3055695A1 (en) 2013-09-12 2016-08-17 Institut National de la Santé et de la Recherche Médicale Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
KR102332302B1 (ko) 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
CA3184564A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2
AU2014333563B9 (en) 2013-10-11 2020-04-02 Oxford Biotherapeutics Ltd Conjugated antibodies against LY75 for the treatment of cancer
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
NZ736970A (en) 2013-12-20 2018-11-30 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
KR102366820B1 (ko) 2014-01-17 2022-02-22 미노믹 인터내셔널 리미티드 진단을 위한 세포 표면 전립선암 항원
EP3653643A1 (en) 2014-02-20 2020-05-20 Allergan, Inc. Complement component c5 antibodies
SG11201606983SA (en) 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
CN106459210A (zh) 2014-03-27 2017-02-22 戴埃克斯有限公司 用于治疗糖尿病黄斑性水肿的组合物和方法
ME03666B (me) 2014-03-28 2020-10-20 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
CA2951391C (en) 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
AU2015274696B2 (en) 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
WO2016016859A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
TW201609811A (zh) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 具有增強之組織分布之雙特異性單鏈抗體構築體
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Constructos de anticuerpos para cdh19 y cd3
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10073098B2 (en) 2015-03-06 2018-09-11 Genentech, Inc. Ultrapurified DsbA and DsbC and methods of making and using the same
WO2016149537A1 (en) 2015-03-17 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bank vole prion protein as a broad-spectrum substrate for rt-quic-based detection and discrimination of prion strains
IL283764B2 (en) 2015-04-10 2024-01-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
HUE061730T2 (hu) 2015-04-17 2023-08-28 Amgen Res Munich Gmbh Bispecifikus antitest-konstrukciók CDH3-hoz és CD3-hoz
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
CN108026180B (zh) 2015-08-28 2022-06-07 豪夫迈·罗氏有限公司 抗羟腐胺赖氨酸抗体及其用途
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
SI3411404T1 (sl) 2016-02-03 2023-01-31 Amgen Research (Munich) Gmbh Konstrukti bispecifičnih protiteles PSMA in CD3, ki aktivirajo T celico
CR20180420A (es) 2016-02-03 2018-12-05 Amgen Inc Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
CN109071623B (zh) 2016-05-04 2022-05-27 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
EP3458477A1 (en) 2016-05-16 2019-03-27 Baxalta Incorporated Anti-factor ix padua antibodies
CA3030834A1 (en) 2016-07-15 2018-01-18 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
MX2019008348A (es) 2017-01-18 2019-10-21 Genentech Inc Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas.
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
AR111773A1 (es) 2017-05-05 2019-08-21 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración
EP3694890A4 (en) 2017-10-12 2021-11-03 Immunowake Inc. LIGHT CHAIN ANTIBODY FUSION PROTEIN WITH VEGFR
EA202091422A1 (ru) 2017-12-11 2020-08-28 Эмджен Инк. Способ непрерывного производства продуктов на основе биспецифических антител
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
JP2021522286A (ja) 2018-04-30 2021-08-30 メディミューン リミテッド 凝集体を標的とし、一掃するためのコンジュゲート
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
BR112020026724A2 (pt) 2018-07-02 2021-03-30 Amgen Inc. Proteína de ligação ao antígeno anti-steap1
US20210301017A1 (en) 2018-07-30 2021-09-30 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
TW202045711A (zh) 2019-06-13 2020-12-16 美商安進公司 生物製品製造中基於生物量之自動灌注控制
JP2022544236A (ja) 2019-08-13 2022-10-17 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
US20220306741A1 (en) 2019-09-10 2022-09-29 Amgen Inc. Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
CA3162705A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
PE20231504A1 (es) 2020-04-30 2023-09-26 Genentech Inc Anticuerpos especificos para kras y sus usos
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
JP2023527972A (ja) 2020-05-29 2023-07-03 アムジエン・インコーポレーテツド Ｃｄ３３及びｃｄ３に結合する二重特異性コンストラクトの有害作用軽減投与
JP2023530600A (ja) 2020-06-01 2023-07-19 ジェネンテック， インコーポレイテッド 細胞外ベシクルの製造するための方法及びその使用
EP4169949A1 (en) 2020-06-23 2023-04-26 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-cd38 antibody and use thereof
EP4182688A1 (en) 2020-07-14 2023-05-24 F. Hoffmann-La Roche AG Assays for fixed dose combinations
CN116323671A (zh) 2020-11-06 2023-06-23 安进公司 具有增加的选择性的多靶向性双特异性抗原结合分子
WO2022212831A1 (en) 2021-04-02 2022-10-06 Amgen Inc. Mageb2 binding constructs
CA3217180A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
CN113372514B (zh) * 2021-06-22 2022-06-14 安徽农业大学 一种刀豆蛋白聚合物水凝胶的制备方法、制得的水凝胶及其应用
WO2023218027A1 (en) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3574062A (en) * 1967-04-20 1971-04-06 Beckman Instruments Inc Method of immobilizing enzymes and product
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (it) * 1967-12-20 1972-03-06 Pharmacia Ab
FR1603393A (it) * 1967-12-27 1971-04-13
DE1908290C3 (de) * 1969-02-19 1982-04-08 Boehringer Mannheim Gmbh, 6800 Mannheim Acrylamid-mischpolymerisat
GB1316990A (en) * 1970-09-17 1973-05-16 Roche Products Ltd Imidazolyl derivatives
AT317424B (de) * 1971-06-09 1974-08-26 Boehringer Mannheim Gmbh Verfahren zur Herstellung von trägergebundenen Proteinen

Also Published As

Publication number Publication date
US3969287A (en) 1976-07-13
JPS4986587A (it) 1974-08-19
HU169972B (it) 1977-03-28
SU524521A3 (ru) 1976-08-05
CH619003A5 (it) 1980-08-29
DK141555C (da) 1980-09-22
SE420498B (sv) 1981-10-12
CA1023287A (en) 1977-12-27
ZA739318B (en) 1974-11-27
DK141555B (da) 1980-04-21
JPS5749197B2 (it) 1982-10-20
IL43476A (en) 1976-03-31
BE808354A (fr) 1974-06-07

Similar Documents

Publication Publication Date Title
IT1045912B (it) Proteina supportata e procedimento per la sua preparazione
IT1050474B (it) Mentil, estere, particolarmente per dentifrici, e procedimento per la sua preparazione
IT985844B (it) Pigmento ceramico e procedimento per la sua fabbricazione
DK135362C (da) Harkosmetiske preparater
IT980547B (it) Transistore ripolare e procedimento per la sua fabbricazione
IT991577B (it) Prodotto alimentare e procedimento per la sua preparazion
IT951435B (it) Proteina supportata e procedimen to per la sua preparazione
IT1047919B (it) Composizione per il fissaggio dei capelli e procedimento per la sua applicazione
IT994105B (it) Composizione autoadesiva e metodo per la sua preparazione
TR17197A (tr) Sjda coezuenmeyen yeni protein preparatlari
IT977791B (it) Convettore e procedimento per la sua fabbricazione
IT984342B (it) Catalizzatore metallico solforato sopportato e procedimento per la sua preparazione
IT1000562B (it) Cuoio sintetico e procedimento per la sua preparazione
IT981464B (it) Proteasi microbica e sua preparazione
IT994533B (it) Frutto artificiale e procedimento per la sua fabbricazion
IT1004607B (it) Composizione acrilica per rivestimenti e procedimento per la sua preparazione
BE807704A (fr) Peptides
IT991590B (it) Composizione alimentare e procedi mento per la sua preparazione
IT982860B (it) Dentrificio aromatizzato e metodo per la sua preparazione
IT980717B (it) Dipeptide e procedimento per la sua produzione
IT941534B (it) Proteina modificata e procedimen to per la sua preparazione
DK137800B (da) Vandoploeselige proteinpraeparater og fremgangsmaade til fremstilling deraf
IT972330B (it) Erbicida contenente clorocarboni luree sostituite e procedimento per la sua preparazione
BE796233A (fr) Preparations pour la chevelure
IT1003274B (it) Sviluppatore fisico fotografico stabilizzato e procedimento per la sua applicazione